Compare Arqit Quantum Inc (ARQQ) vs Mesoblast Limited (MESO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Arqit Quantum Inc vs Mesoblast Limited — how do they compare? Arqit Quantum Inc trades at $18.86 (market cap $332.04M), while Mesoblast Limited trades at $16.01 (market cap $2.00B). The key difference: Mesoblast Limited is far larger — about 6× Arqit Quantum Inc's market cap, and Mesoblast Limited is trading nearer its 52-week high, Arqit Quantum Inc nearer its low. Which is the better fit depends on your goals.
| ARQQ | MESO | |
|---|---|---|
Market Cap | $332.04M | $2.00B |
Sector | Technology | Technology |
52-Week High | $58.27 | $20.96 |
52-Week Low | $11.78 | $10.96 |
Enterprise Value | $305.35M | $2.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARQQ trades at $19.08, down 6.79% today, with a bearish technical signal from moving averages. The company reported $530K revenue for 2025 but a net loss of $35.34M, with negative profit margins and high valuation ratios. Recent news highlights contract wins and 829% YoY revenue growth in H1 FY26, though earnings misses persist.
Outlook remains speculative given deep losses and high P/S of 275.84, but growth in quantum security deals offers potential. Key risks include cash burn and competitive threats. Analyst consensus is split 50/50 buy/hold, indicating cautious optimism amid fundamental challenges.
MESO trades at $15.44, up 4.11% today, with a bullish technical signal from moving averages but overbought RSI near 89. The company reported a net loss of $102.14 million in 2025 despite an 80.52% gross margin, while recent news highlights Ryoncil revenue growth and FDA progress for its heart failure treatment, signaling a transition to commercial operations.
The outlook is cautiously optimistic, driven by product commercialization and pipeline advancements, but high cash burn and negative margins pose significant risks. Analyst consensus leans buy (45% of ratings), yet the stock's elevated P/S ratio of 30.52 demands careful valuation assessment amid ongoing losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arqit Quantum Inc
Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.
Read more on ARQQ →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
